Oncolytics Biotech Rises on Further Cancer Treatment Data
|168 Beiträge ausgeblendet.|| |
irgendwie nix halbes nix ganzes die Ergebnisse...
mal schauen was der Markt dazu sagt..
This is one of a total of six randomized Phase II studies with REOLYSIN® that were designed and sponsored by third parties. The results from these studies will determine clinical targets, endpoints, and study designs for follow on and registration studies conducted by Oncolytics. In the case of this ovarian cancer study, we are pleased that REOLYSIN® has demonstrated a statistically significant reduction in tumour burden in ovarian cancer patients as measured by CA-125 levels," said Dr. Brad Thompson , President and CEO of Oncolytics. "This adds to our results in other indications that have shown improvement in tumour responses. In order to further our understanding of how REOLYSIN® interacts with the immune system, we hope, in conjunction with the principal investigator, to analyze the PD-1 and CD8+ T lymphocyte levels of patients on entry and correlate these with overall survival and progression free survival."